Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Thursday, August 14, 2008

Parexel closes ClinPhone purchase

By Mass High Tech Staff


Pharmaceutical services provider Parexel International Corp. reports it has closed on its previously announced purchase of U.K. firm ClinPhone plc, in a deal earlier reported to be worth $182 million.

Waltham-based Parexel (Nasdaq: PRXL) says that it will combine ClinPhone, a clinical technology firm, with Perceptive Informatics, Parexel’s wholly-owned subsidiary that provides e-clinical technology.

Steve Kent, former CEO of ClinPhone, has been named as the new president of Perceptive Informatics. The subsidiary’s services are designed to help biopharmaceutical companies improve their clinical trial process improvements through such functions as electronic capture of patient data and data collaboration tools, according to Parexel officials.

Founded in 1993, ClinPhone provides telephone and web-based systems used in clinical trials around the world. The Nottingham, England, firm listed 731 employees as of February 2008.

Parexel, with 6,485 workers, reported 2007 net income of $37.3 million on revenue of $918.1 million.




 

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.